Clinical Trial Update: A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial update announces recruitment for KN026 in combination with HB1801, with or without carboplatin, as neoadjuvant therapy for early or locally adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• HB1801
• KN026

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Early or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING